Based on existing evidence into socio-demographic, familial, and clinical factors25, we grouped variables a priori on the anticipated strength of association with the outcome in decreasing levels of priority26,27. All variables were categorised in this way in a protocol before any statistical analys...
The first generation anti-oxMIF antibody imalumab (synonyms: BAX69, BaxB01) demonstrated promising results in a phase I clinical trial with an acceptable safety profile [19]. However, imalumab showed an unusually short half-life in patients, increased aggregation propensity, and an unfavorable ph...